论文部分内容阅读
Objective Non-small cell lung cancer(NSCLC)is the most common and lethal human malignant tumor worldwide.EGFR-TKI is the most widely used targeted therapy in lung cancer patients and it has significantly improved the overall survival of Chinese lung cancer patients.